Tagista, tablets 16 mg 30 pcs

Betahistine acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS.

By direct agonist effect on H1-receptors of the inner ear vessels and indirectly through the effect on NZ-receptors it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea.

At the same time betahistine increases blood flow in the basilar artery.

It has a strong central effect being an inhibitor of NZ-receptors of the vestibular nerve nuclei.

It normalizes the conduction in neurons of the vestibular nuclei at the level of the brain stem.

Clinical manifestation of these properties is reducing the frequency and intensity of dizziness, tinnitus reduction, improvement of hearing in case of its reduction.

Pharmacokinetics

Absorbed quickly, binding with plasma proteins is low. Time to reach maximum concentration in plasma – 3 hours.

It is almost completely eliminated by kidneys in the form of metabolite (2-pyridylacetic acid) within 24 hours. The elimination half-life is 3-4 hours.

Indications

Dizziness, Meniere’s Disease, Impaired cerebral circulation

• Treatment and prevention of vestibular dizziness of various origins;
• Syndromes including vertigo, headache, tinnitus, progressive hearing loss, nausea and vomiting;
• Hypnotics including dizziness, headache, tinnitus, nausea and vomiting
• Syndromes including vertigo and headache, tinnitus, progressive hearing loss, nausea and vomiting;
• Meniere’s disease or syndrome.

.

Active ingredient

Betahistine

Composition

1 tablet contains

Active substance:

Betahistine dihydrochloride 8.0 mg; 16.0 mg; 24.0 mg;

Auxiliary substances:

Microcrystalline cellulose, 54.75/109.5/164.25 mg,

Povidone (collidone 25) – 9.0/18.0/27.0 mg

Potato starch – 20.0/40.0/60.0 mg,

Citric acid – 2.0/4.0/6.0 mg,

Silicon dioxide colloid (aerosil), – 3.0/6.0/9.0 mg,

/p>

Talc – 2.8/5.6/8.4 mg,

Magnesium stearate – 0.45/0.9/1.35 mg.

How to take, the dosage

Orally, with meals.

Tablets 16 mg: 1/2-1 tablet 3 times a day.

Improvement is usually noticed at the beginning of therapy, stable therapeutic effect occurs after two weeks of treatment and may increase over several months of treatment.

The treatment is prolonged. The duration of the treatment course is determined individually.

Interaction

There are no known cases of interaction or incompatibility with other drugs.

Special Instructions

Effect on the ability to drive vehicles and operate machinery

Betahistine has no sedative effect and does not affect the ability to drive a car or engage in activities requiring rapid psychomotor reactions.

Contraindications

• High sensitivity to any of the drug components;
• Age under 18 years (due to lack of data)
• Pregnancy and lactation (due to lack of data).

With caution

Gastric or duodenal ulcer (including anamnesis), pheochromocytoma, bronchial asthma.

These patients should be regularly monitored during treatment.

Side effects

Gastrointestinal disorders. occurrence of hypersensitivity reactions from the skin (rash, itching, urticaria), Quincke’s edema.

Overdose

Symptoms: nausea, vomiting, seizures.

Treatment: gastric lavage, intake of activated charcoal, symptomatic therapy.

.

Similarities

Betaserk, Vestibo, Betahistine, Betahistine NW, Tagista, Vertran